Zacks Investment Research on MSN
NTLA falls 4% despite strong phase III HAE data, initiates rolling BLA
Shares of Intellia Therapeutics NTLA declined 4% on Monday despite positive top-line data from the global phase III HAELO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results